therapeutic-proteins
(2)
Cyrus Sold Protein Software to 120 Drugmakers. Then It Put Its Own Molecules on the Line.
The Seattle spinout made Rosetta easier for pharma scientists, learned from more than 30 partnered discovery programs, and then made a riskier bet: building its own autoimmune drugs. Its story is a useful lesson in when software should become a laboratory - and when that strategy can still fail.
Be Biopharma
Be Biopharma (Be Bio) is a Cambridge, Massachusetts biotechnology company pioneering a new class of therapies called Engineered B Cell Medicines (BCMs). By precisely gene-editing a patient's own B cells - nature's protein factories that can secrete high volumes of protein for decades - Be Bio aims to deliver durable, potentially re-dosable treatments for hemophilia, rare genetic diseases, and other serious conditions. Founded in 2020 out of Seattle Children's Research Institute and Longwood Fund, the company has raised roughly $356 million and, as of early 2025, advanced to a multi-program clinical-stage company led by CEO Joanne Smith-Farrell, Ph.D.